Equities research analysts predict that Advaxis, Inc. (NASDAQ:ADXS) will report earnings of ($0.58) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Advaxis’ earnings, with estimates ranging from ($0.62) to ($0.54). Advaxis reported earnings of ($0.43) per share during the same quarter last year, which would indicate a negative year over year growth rate of 34.9%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 9th.
According to Zacks, analysts expect that Advaxis will report full year earnings of ($2.36) per share for the current fiscal year, with EPS estimates ranging from ($2.62) to ($2.19). For the next financial year, analysts forecast that the company will report earnings of ($2.44) per share, with EPS estimates ranging from ($2.71) to ($2.16). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Advaxis.
Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The company had revenue of $1.76 million during the quarter, compared to analyst estimates of $3.05 million.
In related news, CFO Sara Bonstein sold 12,734 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the transaction, the chief financial officer now directly owns 244,504 shares in the company, valued at $779,967.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the company’s stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The disclosure for this sale can be found here. Insiders sold 638,192 shares of company stock worth $2,702,615 over the last 90 days. 7.21% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in ADXS. Voya Investment Management LLC lifted its position in Advaxis by 20.3% during the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 2,975 shares during the period. PNC Financial Services Group Inc. lifted its position in Advaxis by 18.2% during the second quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 4,000 shares during the period. Stonebridge Capital Management Inc. lifted its position in Advaxis by 88.7% during the third quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 20,045 shares during the period. State of Wisconsin Investment Board bought a new stake in Advaxis during the second quarter worth about $201,000. Finally, The Manufacturers Life Insurance Company lifted its position in Advaxis by 10.4% during the second quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 2,969 shares during the period. Institutional investors and hedge funds own 41.90% of the company’s stock.
Advaxis (ADXS) traded down $0.05 during mid-day trading on Friday, hitting $3.19. 546,524 shares of the company traded hands, compared to its average volume of 796,295. Advaxis has a fifty-two week low of $2.71 and a fifty-two week high of $10.06. The firm has a market capitalization of $128.98, a P/E ratio of -1.39 and a beta of 1.91.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.